R&D Expenses: Research and development expenses for the quarter ended September 30, 2025, were $9.4 million, compared to $9.7 million for the quarter ended September 30, 2024. The expenses were ...
Omalizumab had the greatest risk for adverse effects and dupilumab had the most favorable safety profile among biologics for patients with asthma, according to an abstract presented at the CHEST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback